Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs.

The emerging scientific field of proteomics encompasses the identification, characterization, and quantification of the protein content or proteome of whole cells, tissues, or body fluids. The potential for proteomic technologies to identify and quantify novel proteins in the plasma that can function as biomarkers of the presence or severity of clinical disease states holds great promise for clinical use. However, there are many challenges in translating plasma proteomics from bench to bedside, and relatively few plasma biomarkers have successfully transitioned from proteomic discovery to routine clinical use. Key barriers to this translation include the need for "orthogonal" biomarkers (i.e., uncorrelated with existing markers), the complexity of the proteome in biological samples, the presence of high abundance proteins such as albumin in biological samples that hinder detection of low abundance proteins, false positive associations that occur with analysis of high dimensional datasets, and the limited understanding of the effects of growth, development, and age on the normal plasma proteome. Strategies to overcome these challenges are discussed.

[1]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[2]  M. Konstan,et al.  Sputum biomarkers of inflammation in cystic fibrosis lung disease. , 2007, Proceedings of the American Thoracic Society.

[3]  Julian L Griffin,et al.  Proton NMR analysis of plasma is a weak predictor of coronary artery disease , 2006, Nature Medicine.

[4]  F. Pontén,et al.  Towards a human proteome atlas: High‐throughput generation of mono‐specific antibodies for tissue profiling , 2005, Proteomics.

[5]  G. Church,et al.  Systematic determination of genetic network architecture , 1999, Nature Genetics.

[6]  Tatiana Tatusova,et al.  NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins , 2004, Nucleic Acids Res..

[7]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[8]  P. Sly,et al.  Assay for urinary desmosines in a healthy pre-pubertal population using an improved extraction technique , 2006, Annals of clinical biochemistry.

[9]  S. Carr,et al.  Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S , 2007, Molecular & Cellular Proteomics.

[10]  G. Nicol,et al.  Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. , 2005, Journal of proteome research.

[11]  John Quackenbush,et al.  Genomics and proteomics of lung disease: conference summary. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[12]  J. Granger,et al.  Albumin depletion of human plasma also removes low abundance proteins including the cytokines , 2005, Proteomics.

[13]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[14]  Ivo Safarik,et al.  Magnetic techniques for the isolation and purification of proteins and peptides , 2004, Biomagnetic research and technology.

[15]  P. Angenendt,et al.  Protein and antibody microarray technology. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[17]  T. Hansen,et al.  The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. , 2003, Diabetes.

[18]  N. Blom,et al.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. , 1999, Journal of molecular biology.

[19]  T. Morozova,et al.  Active bead-linked immunoassay on protein microarrays. , 2006, Analytica chimica acta.

[20]  M. Pepe,et al.  Combining diagnostic test results to increase accuracy. , 2000, Biostatistics.

[21]  M. Pawlita,et al.  Suppression of non-specific binding in serological Luminex assays. , 2006, Journal of immunological methods.

[22]  Frank Vitzthum,et al.  Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics , 2006, Expert review of proteomics.

[23]  Thomas J. Wang.  New cardiovascular risk factors exist, but are they clinically useful? , 2008, European heart journal.

[24]  P. Davidsson,et al.  Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples , 2005, Proteomics.

[25]  J. Ware.  The limitations of risk factors as prognostic tools. , 2006, The New England journal of medicine.

[26]  P. Tempst,et al.  Correcting common errors in identifying cancer-specific serum peptide signatures. , 2005, Journal of proteome research.

[27]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[28]  Jeffrey R. Whiteaker,et al.  Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. , 2007, Analytical biochemistry.

[29]  Birgit Kersten,et al.  Multiplex approaches in protein microarray technology , 2005, Expert review of proteomics.

[30]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[31]  Eugene W. Myers,et al.  Basic local alignment search tool. Journal of Molecular Biology , 1990 .

[32]  B. A. Jameson,et al.  The antigenic index: a novel algorithm for predicting antigenic determinants , 1988, Comput. Appl. Biosci..

[33]  F. Accurso,et al.  Proteomics in pediatric research and practice. , 2007, Advances in pediatrics.

[34]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Chris Sander,et al.  Characterizing gene sets with FuncAssociate , 2003, Bioinform..

[36]  Maria Jesus Martin,et al.  The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..

[37]  M. Snyder,et al.  Protein chip technology. , 2003, Current opinion in chemical biology.

[38]  J. Scheuermann,et al.  Affinity-capture reagents for protein arrays. , 2002, Trends in biotechnology.

[39]  S. Brunak,et al.  Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. , 2005, Glycobiology.

[40]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[41]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[42]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[43]  Tiedong Guo,et al.  Steroid profiles using liquid chromatography-tandem mass spectrometry with atmospheric pressure photoionization source. , 2004, Archives of pathology & laboratory medicine.